Azevedo Judi L, Feldman Ricardo A
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Genes Cancer. 2010 Nov;1(11):1089-99. doi: 10.1177/1947601911401908.
The advent of induced pluripotent stem cells (iPSCs) has brought the goal of using patient-derived cells for tissue repair closer to reality. However, the mechanisms involved in reprogramming to a pluripotent state are still not clear. It is understood that reprogramming to pluripotency involves epigenetic remodeling and the reactivation of "core" pluripotency factors. However, little is known about the mechanisms involved in overcoming senescence while avoiding oncogenesis, the maintenance of self-renewal, and the regulation of the balance between pluripotency and differentiation. Here, we review recent advances in reprogramming technology and what is currently known about the mechanism of reprogramming to pluripotency. Work with patient-derived iPSCs is already providing new insights into the cellular and molecular mechanisms involved in human disease. Further advances in reprogramming technology should result in efficient methods to reprogram patient-derived cells into iPSCs for use in regenerative medicine.
诱导多能干细胞(iPSC)的出现使利用患者来源的细胞进行组织修复这一目标更接近现实。然而,重编程为多能状态所涉及的机制仍不清楚。据了解,重编程为多能性涉及表观遗传重塑和“核心”多能性因子的重新激活。然而,对于在克服衰老同时避免肿瘤发生、维持自我更新以及调节多能性与分化之间平衡所涉及的机制,我们知之甚少。在此,我们综述了重编程技术的最新进展以及目前对重编程为多能性机制的了解。利用患者来源的iPSC开展的研究已为人类疾病所涉及的细胞和分子机制提供了新见解。重编程技术的进一步进展应能产生将患者来源的细胞高效重编程为iPSC以用于再生医学的方法。